Sanara MedTech (Sanara MedTech) Long-Term Capital Lease Obligation

: $1.74 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Sanara MedTech's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.74 Mil.

Sanara MedTech's quarterly Long-Term Capital Lease Obligation increased from Jun. 2023 ($1.78 Mil) to Sep. 2023 ($1.85 Mil) but then declined from Sep. 2023 ($1.85 Mil) to Dec. 2023 ($1.74 Mil).

Sanara MedTech's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($0.22 Mil) to Dec. 2022 ($0.51 Mil) and increased from Dec. 2022 ($0.51 Mil) to Dec. 2023 ($1.74 Mil).

Sanara MedTech Long-Term Capital Lease Obligation Historical Data

The historical data trend for Sanara MedTech's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanara MedTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

0.48

0.36

0.22

0.51

1.74

Sanara MedTech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation																0.51	1.86	1.78	1.85	1.74

Sanara MedTech (NAS:SMTI) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Sanara MedTech Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Sanara MedTech's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanara MedTech (Sanara MedTech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sanara MedTech Inc (NAS:SMTI) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102

Website

https://www.sanaramedtech.com

Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel.

Executives

Eric D Major	director	751 MILLER DRIVE SE, LEESBURG VA 20175
Zachary B. Fleming	officer: President - Surgical Div.	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Shawn M. Bowman	officer: President - Wound Care Div.	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Rebecca E Mcmahon	officer: President - R&D	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Sara N Ortwein	director	5959 LAS COLINAS BOULEVARD, IRVING TX 75039-2298
Robert Andrew Desutter	director	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Eric D Tanzberger	director	1929 ALLEN PARKWAY, HOUSTON TX 77219
Christopher A. Morrison	officer: President - Telehealth Svcs.	1200 SUMMIT AVENUE, SUITE 414, FORT WORTH TX 76102
Roszell Iii Mack	director	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Cgi Cellerate Rx, Llc	10 percent owner	C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Catalyst Rochal, Llc	10 percent owner	C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Bradley J. Gurasich	10 percent owner	C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
J Michael Carmena	director, officer: Principal Executive Officer	1200 SUMMIT AVE STE 414, FORT WORTH TX 76102
Michael D. Mcneil	officer: Chief Financial Officer	1200 SUMMIT AVE, STE 414, FORT WORTH TX 76102
Catalyst Group, Inc.	10 percent owner	1375 ENCLAVE PARKWAY, HOUSTON TX 77077